DK1231910T3 - Pentamidin til behandling af cancer - Google Patents
Pentamidin til behandling af cancerInfo
- Publication number
- DK1231910T3 DK1231910T3 DK00975725T DK00975725T DK1231910T3 DK 1231910 T3 DK1231910 T3 DK 1231910T3 DK 00975725 T DK00975725 T DK 00975725T DK 00975725 T DK00975725 T DK 00975725T DK 1231910 T3 DK1231910 T3 DK 1231910T3
- Authority
- DK
- Denmark
- Prior art keywords
- endo
- exonuclease
- compounds
- cancer
- activity
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 6
- 201000011510 cancer Diseases 0.000 title abstract 6
- XDRYMKDFEDOLFX-UHFFFAOYSA-N pentamidine Chemical compound C1=CC(C(=N)N)=CC=C1OCCCCCOC1=CC=C(C(N)=N)C=C1 XDRYMKDFEDOLFX-UHFFFAOYSA-N 0.000 title abstract 2
- 229960004448 pentamidine Drugs 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 7
- 108010051357 endoexonuclease Proteins 0.000 abstract 6
- 230000000694 effects Effects 0.000 abstract 4
- 239000008194 pharmaceutical composition Substances 0.000 abstract 3
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 abstract 2
- 230000002401 inhibitory effect Effects 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 210000002966 serum Anatomy 0.000 abstract 2
- 230000004614 tumor growth Effects 0.000 abstract 2
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 abstract 1
- 229960004316 cisplatin Drugs 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 231100000053 low toxicity Toxicity 0.000 abstract 1
- 229960004857 mitomycin Drugs 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 238000012544 monitoring process Methods 0.000 abstract 1
- 230000002195 synergetic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US16568899P | 1999-11-16 | 1999-11-16 | |
| PCT/CA2000/001355 WO2001035935A2 (en) | 1999-11-16 | 2000-11-16 | Inhibitors of endo-exonuclease activity such as pentamidine for the treatment of cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK1231910T3 true DK1231910T3 (da) | 2009-08-31 |
Family
ID=22600019
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK00975725T DK1231910T3 (da) | 1999-11-16 | 2000-11-16 | Pentamidin til behandling af cancer |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US20060276548A1 (da) |
| EP (1) | EP1231910B1 (da) |
| JP (1) | JP2003515534A (da) |
| AT (1) | ATE431734T1 (da) |
| AU (1) | AU780538B2 (da) |
| CA (1) | CA2388674C (da) |
| CY (1) | CY1110503T1 (da) |
| DE (1) | DE60042245D1 (da) |
| DK (1) | DK1231910T3 (da) |
| ES (1) | ES2327313T3 (da) |
| PT (1) | PT1231910E (da) |
| WO (1) | WO2001035935A2 (da) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2001266838A1 (en) * | 2000-06-21 | 2002-01-02 | Georgetown University | Inhibitors of matriptase for the treatment of cancer |
| US6569853B1 (en) | 2000-11-06 | 2003-05-27 | Combinatorx, Incorporated | Combinations of chlorpromazine and pentamidine for the treatment of neoplastic disorders |
| US6693125B2 (en) | 2001-01-24 | 2004-02-17 | Combinatorx Incorporated | Combinations of drugs (e.g., a benzimidazole and pentamidine) for the treatment of neoplastic disorders |
| US8053477B2 (en) * | 2002-03-29 | 2011-11-08 | University Of Maryland, Baltimore | Inhibitors of the S100-p53 protein-protein interaction and method of inhibiting cancer employing the same |
| ITMI20021455A1 (it) * | 2002-07-02 | 2004-01-02 | Ugo Raffaello Citernesi | Formulazioni fosfolipidiche di lexitropsine loro preparazione ed impiego terapeutico |
| US20050054708A1 (en) * | 2003-07-28 | 2005-03-10 | Nichols Matthew James | Combinations of drugs for the treatment of neoplasms |
| US20100028339A1 (en) | 2004-03-29 | 2010-02-04 | Cheng Jin Q | Compositions including triciribine and trastuzumab and methods of use thereof |
| AU2005228410A1 (en) | 2004-03-29 | 2005-10-13 | University Of South Florida | Effective treatment of tumors and cancer with triciribine and related compounds |
| US20100009928A1 (en) | 2004-03-29 | 2010-01-14 | Cheng Jin Q | Compositions including triciribine and taxanes and methods of use thereof |
| US20100173864A1 (en) | 2004-03-29 | 2010-07-08 | Cheng Jin Q | Compositions including triciribine and one or more platinum compounds and methods of use thereof |
| US20110008327A1 (en) | 2004-03-29 | 2011-01-13 | Cheng Jin Q | Compositions including triciribine and epidermal growth factor receptor inhibitor compounds or salts thereof and methods of use thereof |
| US20100009929A1 (en) | 2004-03-29 | 2010-01-14 | Cheng Jin Q | Compositions including triciribine and bortezomib and derivatives thereof and methods of use thereof |
| WO2006062072A1 (ja) * | 2004-12-10 | 2006-06-15 | Tmrc Co., Ltd. | 転移癌治療剤および癌転移抑制剤 |
| CA2713428C (en) | 2007-12-28 | 2015-03-31 | Server Technology, Inc. | Power distribution, management, and monitoring systems and methods |
| WO2010125462A2 (en) * | 2009-05-01 | 2010-11-04 | Oncozyme Pharma Inc. | Pentamidine combinations for treating cancer |
| WO2014008592A1 (en) * | 2012-07-13 | 2014-01-16 | Oncozyme Pharma Inc. | Combinations comprising diamidine compounds and parp inhibitors for use iν treating cancer |
| WO2019095046A1 (en) | 2017-11-16 | 2019-05-23 | Montdorex Inc. | Mono- and di-amidine endo-exonuclease inhibitors and methods for inhibiting endo-exonuclease activity |
| CN115998872B (zh) * | 2020-04-15 | 2025-03-25 | 四川大学华西第二医院 | 一种含有抑制核酸内切酶功能的药物及其抗肿瘤的用途 |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2145528C3 (de) * | 1971-09-11 | 1981-12-17 | Heinrich Mack Nachf., 7918 Illertissen | Exonuclease und diese enthaltendes cytostatisches Mittel |
| EP0585957A1 (en) * | 1986-08-06 | 1994-03-09 | Ajinomoto Co., Inc. | Recombinant B-cell differentiation factor |
| JP2770970B2 (ja) * | 1987-04-09 | 1998-07-02 | フアイソンズ・ピーエルシー | ペンタミジンを含有する医薬組成物 |
| US5204113A (en) * | 1987-04-09 | 1993-04-20 | Fisons Plc | Pharmaceutical compositions containing pentamidine |
| US5166140A (en) * | 1987-05-05 | 1992-11-24 | City Of Hope | Use of certain nucleoside analogs to attenuate cancer cell resistance to DNA damaging chemotherapy |
| US5585363A (en) * | 1987-05-05 | 1996-12-17 | City Of Hope | Circumvention of human tumor drug resistance |
| US4856528A (en) * | 1987-06-26 | 1989-08-15 | John Hopkins University | Tumor volume determination |
| US5204352A (en) * | 1987-09-29 | 1993-04-20 | The United States Of America As Represented By The Secretary Of The Army | Compounds exhibiting anti-parasitic activity and a method for their use |
| US5084480A (en) * | 1987-11-06 | 1992-01-28 | Fujisawa Usa, Inc. | Pentamidine salts useful in the treatment of pneumocystis carinii pneumonia |
| US5422120A (en) * | 1988-05-30 | 1995-06-06 | Depotech Corporation | Heterovesicular liposomes |
| MX16687A (es) * | 1988-07-07 | 1994-01-31 | Ciba Geigy Ag | Compuestos de biarilo y procedimiento para su preparacion. |
| US5037758A (en) * | 1989-01-11 | 1991-08-06 | Her Majesty The Queen In Right Of Canada, As Represented By The National Research Council Of Canada | Enhanced production of biosurfactant through the use of a mutated B subtilis strain |
| GB8903438D0 (en) * | 1989-02-15 | 1989-04-05 | May & Baker Ltd | New compositions of matter |
| US5352581A (en) * | 1989-03-24 | 1994-10-04 | United States/National Institutes Of Health | Sensitive yeast genetic system for identifying agents causing double-stranded DNA damage |
| AU7162791A (en) * | 1989-12-27 | 1991-07-24 | Miroslav Radman | Novel system for isolating and producing new genes, gene products and dna sequences |
| US5489524A (en) * | 1991-03-26 | 1996-02-06 | The United States Of America As Represented By The Department Of Health And Human Services | Chimeric protein that has a human Rho motif and deoxyribonuclease activity |
| US5324830A (en) * | 1991-03-26 | 1994-06-28 | United States Of America | Chimeric protein that has a human RHo Motif and deoxyribonuclease activity |
| US5283238A (en) * | 1992-04-24 | 1994-02-01 | Immtech International, Inc. | Methods of treating cancer using modified C-reactive protein |
| US5723288A (en) * | 1994-05-06 | 1998-03-03 | The University Of North Carolina At Chapel Hill | Method of fluorescent detection of nucleic acids and cytoskeleton elements using bis-dicationic aryl furans, and kits useful therefor |
| US5874283A (en) * | 1995-05-30 | 1999-02-23 | John Joseph Harrington | Mammalian flap-specific endonuclease |
| US5643935A (en) * | 1995-06-07 | 1997-07-01 | The University Of North Carolina At Chapel Hill | Method of combatting infectious diseases using dicationic bis-benzimidazoles |
| US5698556A (en) * | 1995-06-07 | 1997-12-16 | Chan; Carcy L. | Methotrexate analogs and methods of using same |
| US5916779A (en) * | 1995-09-21 | 1999-06-29 | Becton, Dickinson And Company | Strand displacement amplification of RNA targets |
| US5935982A (en) * | 1997-02-28 | 1999-08-10 | The University Of North Carolina At Chapel Hill | Methods of treating retroviral infection and compounds useful therefor |
| US5977311A (en) * | 1997-09-23 | 1999-11-02 | Curagen Corporation | 53BP2 complexes |
| EP1022286A4 (en) * | 1997-10-07 | 2003-04-09 | Ono Pharmaceutical Co | POLYPEPTIDES, FOR ENDING CODNA AND THEIR USE |
| US7115665B1 (en) * | 2000-11-16 | 2006-10-03 | Onocozyme Pharma, Inc. | Inhibitors of endo-exonuclease activity for treating cancer |
| CN101532001A (zh) * | 2000-03-08 | 2009-09-16 | 诺维信公司 | 具有改变的特性的变体 |
| US6569853B1 (en) * | 2000-11-06 | 2003-05-27 | Combinatorx, Incorporated | Combinations of chlorpromazine and pentamidine for the treatment of neoplastic disorders |
| US6693125B2 (en) * | 2001-01-24 | 2004-02-17 | Combinatorx Incorporated | Combinations of drugs (e.g., a benzimidazole and pentamidine) for the treatment of neoplastic disorders |
| US20040010045A1 (en) * | 2001-09-07 | 2004-01-15 | Taolin Yi | Therapeutic compositions comprised of pentamidine and methods of using same to treat cancer |
| US8053477B2 (en) * | 2002-03-29 | 2011-11-08 | University Of Maryland, Baltimore | Inhibitors of the S100-p53 protein-protein interaction and method of inhibiting cancer employing the same |
-
2000
- 2000-11-16 PT PT00975725T patent/PT1231910E/pt unknown
- 2000-11-16 CA CA002388674A patent/CA2388674C/en not_active Expired - Fee Related
- 2000-11-16 DE DE60042245T patent/DE60042245D1/de not_active Expired - Lifetime
- 2000-11-16 AU AU13765/01A patent/AU780538B2/en not_active Ceased
- 2000-11-16 AT AT00975725T patent/ATE431734T1/de active
- 2000-11-16 WO PCT/CA2000/001355 patent/WO2001035935A2/en not_active Ceased
- 2000-11-16 ES ES00975725T patent/ES2327313T3/es not_active Expired - Lifetime
- 2000-11-16 JP JP2001537928A patent/JP2003515534A/ja active Pending
- 2000-11-16 EP EP00975725A patent/EP1231910B1/en not_active Expired - Lifetime
- 2000-11-16 DK DK00975725T patent/DK1231910T3/da active
-
2006
- 2006-05-25 US US11/420,358 patent/US20060276548A1/en not_active Abandoned
-
2008
- 2008-08-27 US US12/199,603 patent/US20090068094A1/en not_active Abandoned
-
2009
- 2009-08-11 CY CY20091100855T patent/CY1110503T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP1231910A2 (en) | 2002-08-21 |
| US20060276548A1 (en) | 2006-12-07 |
| PT1231910E (pt) | 2009-08-06 |
| WO2001035935A3 (en) | 2002-01-03 |
| WO2001035935A2 (en) | 2001-05-25 |
| JP2003515534A (ja) | 2003-05-07 |
| AU780538B2 (en) | 2005-03-24 |
| AU1376501A (en) | 2001-05-30 |
| CA2388674C (en) | 2005-01-25 |
| CA2388674A1 (en) | 2001-05-25 |
| EP1231910B1 (en) | 2009-05-20 |
| ATE431734T1 (de) | 2009-06-15 |
| CY1110503T1 (el) | 2015-04-29 |
| US20090068094A1 (en) | 2009-03-12 |
| WO2001035935B1 (en) | 2002-02-07 |
| ES2327313T3 (es) | 2009-10-28 |
| DE60042245D1 (de) | 2009-07-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1110503T1 (el) | Πενταμιδινη για θεραπεια καρκινου | |
| WO2007103114A3 (en) | Notch inhibition in the treatment or prevention of atherosclerosis | |
| PT1660507E (pt) | Inibidores de proteassoma e seus métodos de utilização | |
| ATE362363T1 (de) | Verwendung von tnf-alpha inhibitoren zur behandlung von nervenwurzelschäden | |
| ATE241358T1 (de) | Verwendung von cholinesterasehemmer zur behandlung von konzentrationsstörungen | |
| DE60029799D1 (de) | Verbindungen, verfahren und pharmazeutische zubereitungen zur behandlung von zellschäden wie zum beispiel schäden an nerven- oder kerzgefässgewebe | |
| MX342128B (es) | Compuestos farmaceuticos. | |
| EA200600078A1 (ru) | Способы и композиции для лечения амилоидных заболеваний | |
| ATE411018T1 (de) | Verfahren zur behandlung oder verhinderung von vaskulärer entzündung mit sterol-absorbierungs- inhibitor(en) | |
| ATE345793T1 (de) | Behandlung von xanthom mittels azetidinon- derivate als hemmer der sterol absorption | |
| ATE452884T1 (de) | Arylmethylamin-derivate zur verwendung als inhibitoren von tryptase | |
| ATE318606T1 (de) | Zusammenstellungen zur prophylaxe und behandlung von allergien des typus i | |
| ATE497763T1 (de) | Verfahren und reagenzien zur behandlung von entzündlichen erkrankungen | |
| ATE557087T1 (de) | Verfahren und kit zum nachweis von sklerose verursachenden proliferativen erkrankungen und/oder heilmittel gegen sklerose verursachende proliferative erkrankungen sowie verfahren und kit zur identifizierung einer bei der vorbeugung und/oder behandlung von sklerose verursachenden proliferativen erkrankungen wirksamen substanz | |
| BR0311136A (pt) | composto ou um sal, enanciÈmero, diaestereÈmero ou éster hidrolisável in vivo ou mistura dos mesmos farmaceuticamente aceitável, composição, e, método para inibir a atividade de fator letal (lf) liberado de bactérias em um mamìfero | |
| ATE454465T1 (de) | In-vitro-verfahren zur identifizierung von verbindungen zur krebstherapie | |
| ATE290857T1 (de) | Bretyliumhaltige zusammensetzungen und kits und deren verwendung zur vorbeugung und behandlung cardiovaskulärer erkrankungen | |
| WO2000057871A3 (en) | Methods for identifying agents that inhibit serum aging factors and uses and compositions thereof | |
| ATE550661T1 (de) | Krebsdiagnose und behandlung unter verwendung eines anti-robo1-antikörper | |
| DE602004022423D1 (de) | Hemmung der s6-kinase-aktivität zur behandlung von insulinresistenz | |
| ATE547105T1 (de) | Glucosamin und derivate davon als transglutaminase-inhibitoren zur verwendung in der behandlung von einer funktionsstörung des nervensystems | |
| ATE360438T1 (de) | Verwendung von inaktives cln2 proenzym zur behandlung von lincl | |
| ATE407925T1 (de) | 1,4-dihydropyridinverbindungen, pharmazeutische verbindungen, und verfahren zur behandlung von herzkreislauferkrankungen | |
| DE602004016841D1 (de) | Verwendung von 2,2,3,3, tetramethylcyclopropane carbonsäure derivaten zur behandlung von psychiatrischen störungen | |
| DE69838002D1 (de) | Substituierte 11-phenyl-dibenzazepin-verbindungen, die nützlich sind zur behandlung oder vorbeugung von durch abnormale zellproliferation gekennzeichneten krankheiten |